NYSE: MRKMerck & Co Inc Stock
$105.38-1.49 (-1.39%)
Updated Jan 27, 2023
MRK Price
$105.38
Fair Value Price
N/A
Market Cap
$267.18B
52 Week Low
$72.88
52 Week High
$115.49
P/E
17.48x
P/B
6.01x
P/S
3.7x
PEG
1.11x
Dividend Yield
2.66%
Revenue
$58.97B
Earnings
$15.26B
Gross Margin
70.5%
Operating Margin
28.43%
Profit Margin
25.9%
Debt to Equity
1.41
Operating Cash Flow
$20B
Beta
0.55
Next Earnings
Feb 2, 2023
Ex-Dividend
Mar 14, 2023
Next Dividend
Apr 10, 2023
MRK Overview
Merck & Company Incorporated develops and distributes prescription medicines, vaccines, biologic therapies, and animal health products. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, NJ.
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRK ($105.38) is trading above its intrinsic value of $70.65, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRK is good value based on its earnings relative to its share price (17.48x), compared to the US market average (23.59x)
P/E vs Market Valuation
MRK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MRK due diligence checks available for Premium users.
Be the first to know about important MRK news, forecast changes, insider trades & much more!
MRK News
Valuation
MRK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.48x
Industry
30.12x
Market
23.59x
MRK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MRK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MRK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.01x
Industry
5.24x
MRK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRK price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRK is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MRK's financial health
Profit margin
Revenue
$15.0B
Net Income
$3.2B
Profit Margin
21.7%
MRK's Earnings (EBIT) of $16.77B... subscribe to Premium to read more.
Interest Coverage Financials
MRK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$107.1B
Liabilities
$62.6B
Debt to equity
1.41
MRK's short-term assets ($33.56B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRK's long-term liabilities ($39.56B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$5.6B
Investing
-$962.0M
Financing
-$2.7B
MRK's operating cash flow ($19.70B)... subscribe to Premium to read more.
Debt Coverage Financials
MRK vs General Drug Manufacturer Stocks
Merck & Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.